The therapeutic potential of peptide drugs has remained unfulfilled due to the unfavorable physicochemical properties of these molecules. Peptides are extremely susceptible to proteolytic degradation in blood and tissues. The hydrophilic nature of peptides severely limits their permeability across hydrophobic cell membranes.
Compared to somatostatin, RC-160 possesses improved anti-proliferative and anti-secretory activity. It is particularly active against breast, prostate, renal and ductal pancreatic cancers and has been successfully used in the therapy of hypersecretory states and AIDS-related diarrhea. [3] [4] [5] Despite the high potency and specificity of RC-160, its application as a clinically useful drug has been problematic because of its short biological half-life and serious delivery problems. The bioactivity of RC-160 is mediated through high affinity Gprotein coupled somatostatin receptors (SSTRs) on target cells. 4, 5) It has been suggested that the inhibitory effect of RC-160 on tumor growth may be mediated directly by SSTRs on cancer cells, or induced indirectly by the inhibition of growth factors such as epidermal growth factor (EGF), insulin like growth factor (IGF)-1, etc. [3] [4] [5] Although somatostatin analogs like octreotide and RC-160 are longer acting than the native hormone, their biological activity of less than 2 h requires either frequent administration, or sustained release formulation, to attain enhanced anti-proliferative activity and a long-term suppression of hormones like growth hormone (GH) and IGF-1. 6 ) Formulations of octreotide and somatuline, made by entrapping the peptide in DL-lactide-co-glycollide polymer microspheres [6] [7] [8] [9] [10] have been shown to display improved anti-proliferative activity and modulation of GH release but their pharmacokinetic properties are not optimal. 7, 8) Somatuline displays an initial burst in drug release whereas octreotide produces an initial delay in peptide release. The administration of these antitumor agents is also limited by their pleotropic nature and side effects like increased incidence of cholesterol gallstones, temporary inhibition and/or delay of insulin release in response to meals and diminished in glucose tolerance in some patients.
11) The acute administration of somatostatin agonists has been observed to produce receptor desensitization, which results in diminished therapeutic response and induction of tolerance. 11) Hence, there is a need for further modification of these analogs to increase their stability and improve their therapeutic index.
Lipophilization (conjugation of fatty acyl moiety) of bioactive peptides, is a novel strategy to increase their stability and biological availability. Unlike sustained release formulations, lipophilization can also impart enhanced receptor selectivity to peptides. [12] [13] [14] The attachment of fatty acids to peptides like vasoactive intestinal peptide (VIP) leads to the generation of a highly potent and selective VIP analogs. [12] [13] [14] Such lipopeptides have provided novel tools in drug design for Alzheimer's disease, hyperproliferative skin disorders and various forms of cancer. [12] [13] [14] [15] [16] [17] [18] [19] [20] Previous studies in our laboratory, have demonstrated that lipophilization of RC-160 with long chain fatty acids improves its GH-inhibitory activity. 15) However, studies investi-gating the effect of lipophilized-somatostatin (or its analogs) on serum-induced proliferation of neoplastic cells and downstream signal transduction mechanisms involved therein,
have not yet been reported. Therefore, the objective of the present study was to evaluate the effect of lipophilization on the anti-neoplastic activity of RC-160, and to determine whether such derivatization of RC-160 could improve its anti-proliferative activity. Furthermore, the effect of varying peptide hydrophobicity (indicated by the carbon chain length of the conjugated fatty acid) on the antiproliferative activity of lipophilized RC-160 was also investigated. This was accomplished by the attachment of fatty acids of carbon chain lengths ranging from 4 to 18, to RC-160. Thereafter, the antiproliferative activities of these lipopeptides were studied. The study also attempted to gain insight into the signaling pathways underlying the bioactivity of these lipopeptides and RC-160 in vitro, in serum induced proliferation of the human breast carcinoma cell line MCF-7.
MATERIALS AND METHODS

Chemicals
Rink amide resin and Fmoc amino acids were purchased from Bachem California, U.S.A. All growth media, antibiotics were purchased from Gibco BRL, U.S.A. Fetal calf serum (FCS) was obtained from Biological Industries, Israel. All other chemicals were obtained from Sigma Chemical Co., U.S.A.
Peptide Synthesis The synthesis of RC-160 was carried out according to the 9-fluorenylmethoxycarbonyl (Fmoc) manual solid phase strategy, employing optimum side chain protection. 15, 21) Saturated fatty acids were conjugated to RC-160 while it was bound to the resin, using a combination of diisopropyl carbodiimide (DIPCDI) and N-hydroxybenztriazole (HOBT), normally employed for extension of the peptide chain. The intramolecular disulfide bond was formed as described earlier.
15) The molecular weight of the lipophilized peptides and the parent peptide was ascertained by electron spray (ES)-mass spectrometry (Fison Instruments, U.K.).
Cell Culture The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection, Bethesda, MA, U.S.A. The cells were maintained in RPMI-1640 medium supplemented with 2 mM glutamine, 25 mM HEPES, 100 units/ml penicillin, 50 mg/ml streptomycin, 40 mg/ml gentamycin and 10% FCS. All cell lines were maintained at 37°C in a humidified atmosphere containing 5% CO 2 in air.
Proliferation Assay Human breast carcinoma cells were cultured to 70% confluence were harvested using 0.05% bovine pancreatic protease-EDTA solution and replated in medium supplemented with 10% FCS, in 96 well microtiter tissue culture plates at a density of 5000 cells/well. The plates were incubated for 36 h to allow complete reattachment of the cells to the wells. Subsequently, the medium was replaced with RPMI-1640 containing 2.5% FCS. The analogs were added twice a day, for 72 h. 3 H thymidine (1 mCi/well; specific activity 2 Ci/mmol, DU PONT NEN, U.S.A.) was added during the last 6 h of incubation.
22) The cells were harvested and collected on glass fiber filters using an automatic cell harvester (Skatron Instruments, Norway). The radioactivity incorporated was measured using a bcounter (Wallac Oy, Finland).
Studies using inhibitors like Tyrphostin 47 and pertussis toxin were done by adding varying doses of these chemicals along with the peptide. The assay was carried out as described above for 72 h. Studies using pertussis toxin were done by incubating MCF-7 cells with 100 ng/ml pertussis toxin, for 18 h prior to the commencement of the assay.
Receptor ]-somatostatin-14 in the presence or absence of various concentrations of RC-160 and unlabelled lipopeptides, for 2 h. The cells were subsequently washed four times with ice cold binding buffer and lysed using 0.3 N NaOH. The radioactivity of the cellular lysate was measured using a gamma counter (LKB Wallac, Finland).
The coupling of receptor subtypes with G-proteins was investigated by incubating the cells with 100 mM guanosine-5-O-(3-thiotriphosphate) (GTPgS). Experiments involving pertussis toxin were performed by treating the cells for 18 h with 100 ng/ml of pertussis toxin before the binding assay.
Tyrosine Kinase Assay Phosphorylation of a broad specificity peptide substrate was performed using a nonradioactive tyrosine kinase assay kit (Boehringer Mannheim, Germany). 1ϫ10 6 cells were treated with the test peptides for about 15 min. The cells were lysed and the tyrosine kinase activity was determined measuring the phosphorylation of a broad specificity peptide, as per the manufacturer's instructions.
Measurement of Intracellular cAMP MCF-7 cells were cultured in 24-well plates at a density of 5ϫ10 4 cells/well, in RPMI-1640 containing 10% FCS, until they became 70% to 80% confluent. Cells were incubated for 30 min at 37°C in an assay buffer consisting of 25 mM Tris-acetate (pH 7.4), 0.25 mM sucrose, 0.5% BSA and 0.5 mM 3-isobutyl-1-methylxanthine (MIBX), in the presence or absence of 1 mM forskolin, RC-160 and lipophilized RC-160. 22) The reaction was terminated by adding ice-cold solution of 0.1 N HCl and 95% ethanol to each well. After freezing at Ϫ70°C overnight, the cellular lysate was spun at 4000 rpm for 10 min. The concentrations of cAMP in the cellular lysate were determined using cAMP RIA kit (DU PONT NEN, U.S.A.), according to the manufacturer's instructions.
Protease Sensitivity The peptide was dissolved in 0.1 M ammonium bicarbonate, 1 M EGTA buffer (pH 8.0), containing 1% dimethyl sulfoxide (DMSO). Bovine pancreatic protease was added to the peptide solution (ratio 1 : 50 w/w). The reaction mixture was incubated at 37°C for 36 h.
23) The progress of the digestion was monitored, using a C 18 reverse phase column, on an HPLC system.
In Vitro Serum Sensitivity The peptide was dissolved in 0.1 M ammonium bicarbonate, 1 M EGTA buffer (pH 8.0), containing 1% DMSO at a concentration of 1 mg/ml. One hundred microliters of the peptide solution was added to 1 ml of normal mouse serum.
15) The reaction mixture was incubated at 37°C for 36 h. The reaction was monitored by re-versed-phase high-performance liquid chromatography (RP-HPLC). At various time intervals, aliquots of the reaction mixture were taken and equal volumes of 100% acetonitrile was added to precipitate the proteins present therein. The suspension was spun at 10000 rpm, and the supernatant was injected into an HPLC system, equipped with a C 18 reverse phase Deltapak column (Nihon Waters, Japan).
Statistical Analysis All data are expressed as the meanϮS.E.M. Mean values between the treatment group and the control group were analyzed by the Student's t-test (Microsoft Excel 98). Data were considered significant when the two-tailed value of p was less than 0.05. Data from receptor binding experiments were analyzed by the Ligand-PC curve-fitting program of Munsen and Rodbard, modified by McPherson.
24) RESULTS
Synthesis, Purification and Characterization of
Lipophilized RC-160 RC-160 was synthesized by the manual solid phase peptide synthesis methodology, as detailed earlier.
15) The yield of the disulfide oxidation reaction was about 9-15%. The peptide was characterized by Nterminal sequencing. The lipopeptides were characterized by ES-mass spectrometry. A good agreement was found between the predicted molecular weights (Table 1) . (Fig. 1) . The concentration of peptide which causes a 50% inhibition of binding of 125 I-[Tyr 1 ]-somatostatin-14 to the above cell lines (IC 50 ) is shown in Table 2 . The receptor affinity of long chain derivatives like myristoyl-RC-160 and pamitoyl-RC-160 are not significantly different from RC-160. However, stearoyl-RC-160 has lower receptor affinity than both pamitoyl-RC-160 and RC-160 itself (pϽ0.01), in the cell line MCF-7. Furthermore, butanoyl-RC-160 also has lower receptor affinity than both pamitoyl-RC-160 and RC-160 itself (pϽ0.001) in human breast cancer cells.
Binding of RC-160 and Its Lipophilized Derivatives on MCF-7 Cells
Anti-proliferative Activity of Lipophilized-RC-160 on MCF-7 Cells in Vitro RC-160 inhibited serum-induced proliferation of the breast carcinoma cells in vitro. Figure 2A shows the anti-proliferative activity of pamitoyl-RC-160, as compared to RC-160. The graph is biphasic in nature, with the maximum anti-proliferative activity (marked with the symbol # on Fig. 2A) , being manifested within a narrow range of peptide concentration. In the presence 1 ng/ml of RC-160, a significant suppression of cell growth was obtained (pϽ0.001); the cell proliferation rate being decreased by 37% (Fig. 2A) . Figure 2B represents the maximum anti- The peptides were synthesized by Fmoc-solid phase methodology. The peptides were purified by RP-HPLC and characterized by ES-mass spectrometry. Fig. 2A ) plotted versus the carbon chain length of the lipopeptides. Figure 2B suggests a few trends regarding the effect of peptide hydrophobicity on the antiproliferative activity of RC-160. The graph shows that long chain lipopeptides like myristoyl-RC-160 and pamitoyl-RC-160 are 10-fold more potent than RC-160 itself whereas butanoyl-RC-160 and stearoyl-RC-160 were found to be 1000-fold less potent, as compared to RC-160, in MCF-7 cells. An interesting observation was that pamitoyl-RC-160 caused a similar suppression of cell growth as RC-160, at a 10-fold lower concentration, in MCF-7 cells.
The anti-proliferative effect of lipophilized RC-160 in vitro, seems to be mediated by the presence of specific somatostatin receptors on MCF-7 cells (Fig. 1) . Both pertussis toxin and GTPgS were able to significantly block the binding of 125 I-[Tyr 1 ]-somatostatin to the receptor (Fig. 3 ) (pϽ0.001). This suggests that RC-160 as well as its lipophilized derivatives, mediate their anti-proliferative activity through pertussis toxin sensitive G-proteins.
Signaling Pathways Underlying the Bioactivity of Lipophilized-RC-160 The anti-proliferative activity of RC-160 and lipopeptides was abrogated 1 mM of tyrophostin 47 (tyrosine kinase inhibitor) implicating the protein tyrosine kinase pathway in the anti-proliferative activity of these peptides (Fig. 4) . Furthermore, co-treatment of MCF-7 cells by 100 ng/ml of pertussis toxin abolished the growth inhibitory Cells were incubated with the peptides, in the presence of medium supplemented with 2.5% FCS. The peptides were added every 12 h, for a period of 72 h. The cells were pulsed with tritiated thymidine, and subsequently counted on a b-counter. # Conc. of the peptide displaying maximum anti-proliferative activity. * * * pϽ0.001 (between myristoyl-RC-160 and RC-160). * * pϽ0.01 (between butanoyl-RC-160 and RC-160). * * * pϽ0.001 (RC-160 and control). The concentration of the lipopeptide displaying the maximum antiproliferative activity (marked with the symbol # on Fig. 2A) was plotted against the carbon chain length of lipophilized-RC-160. Note that the antiproliferative activity seems to increase with peptide hydrophobicity within a defined range of carbon lengths, after which the bioactivity diminishes with increasing chain lengths. ]-somatostatin in the presence of GTPgS for two hours at 4°C. The cells were incubated with 100 ng/ml pertussis toxin for 18 h prior to the receptor binding assay. The receptor binding assay was done as specified in Materials and Methods. The excess radioactivity was washed with binding buffer, the cells were subsequently lysed and counted. * * * pϽ0.001.
Fig. 4. Effect of Tyrosine Kinase Inhibitor Tyrphostin 47 on the Anti-proliferative Effect of RC-160 and Its Lipophilized Derivatives in Vitro
The cells were incubated individually with Tyrphostin 47 (1 mM) and the proliferation assay was done as detailed in the Materials and Methods.
activities of the aforesaid lipopeptides (data not shown).
RC-160 and the lipopeptides were found to potently inhibit protein tyrosine kinase (PTK) activity in MCF-7 cells (Fig. 5A ). In the presence 1 ng/ml of RC-160, a significant inhibition of total PTK activity was obtained (pϽ0.001), in MCF-7 cells (Fig. 5A) ; the enzyme activity being reduced by 51%. The magnitude of inhibition in PTK activity, induced by pamitoyl-RC-160 is similar to RC-160, however the suppression of kinase activity is displayed at a 10-fold lower concentration, than RC-160, in MCF-7 cells (pϽ0.01). However, butanoyl-RC-160 inhibits PTK activity at 1000-fold lower concentration as RC-160.
The treatment of MCF-7 cells with forskolin, an activator of adenylate cyclase, resulted in a dose dependent increase in the production of cAMP (data not shown) with a maximal effect at 10 mM (about 41% increase over control). The lipopeptides and RC-160 potently inhibited forskolin-stimulated intracellular cAMP levels (Fig. 5B) . The hydrophobic lipopeptide pamitoyl-RC-160 displayed improved inhibition of cAMP levels, relative to butanoyl-RC-160 and RC-160 in MCF-7 cells.
Protease and Serum Sensitivity of Lipopeptides versus RC-160 The stability of pamitoyl-RC-160, as compared to RC-160 was assessed by evaluating their susceptibility towards bovine pancreatic protease and serum (Figs. 6A, B) . Pamitoyl-RC-160 exhibited greater stability to bovine pancreatic protease digestion, even after 24 h, as compared to RC-160. In the presence of normal mouse serum, RC-160 was degraded within two hours, whereas pamitoyl-RC-160 was clearly detectable in serum, even after 24 h (Fig. 6B) . The peptides were incubated with crude bovine pancreatic protease in digestion buffer at 37°C, as detailed in Materials and Methods. The reaction was monitored at different time points, using an HPLC system equipped with a C 18 reverse phase column (A). The relative stability of pamitoyl-RC-160 versus RC-160 in normal mouse serum was assessed by incubating the peptides in mouse serum at 37°C (B). The reaction mixture was diluted 1 : 1 with 100% acetonitrile to precipitate the proteins. It was briefly spun at 10000 rpm and the clear supernatant was injected into an RP-HPLC system, equipped with a C 18 column. * * pϽ0.01.
DISCUSSION
Carcinoma of the breast is the most frequently occurring malignancy in women. Around 370000 cases are diagnosed in U.S. and Europe and 89000 deaths occur every year due to this disease. In India, breast cancer accounts for about 20% of all the cancer cases amongst women. 25) Previous studies have demonstrated the role of growth factors, steroid and peptide hormones in the growth regulation of human breast cancer. 26) Somatostatin agonists are potent inhibitors of several growth factors and have been shown to possess direct growth-inhibitory effects on breast cancer in vitro and in vivo. [26] [27] [28] [29] Furthermore, SSTRs have been demonstrated in 36-67% of primary human breast tumors and even up to 75% by in vivo scintigraphy. 27) Hence, several studies have attempted to explore the therapeutic potential of somatostatin agonists (as single agents as well as in combination with other anti-cancer drugs) in breast carcinoma. [26] [27] [28] [29] However, randomized prospective studies have not demonstrated significant therapeutic benefit of somatostatin analog therapy in breast carcinoma in patients. 27) The anti-proliferative activity of somatostatin is mediated by membrane associated G-protein coupled receptors on target cells (SSTRx, xϭ1-5). 4, 30) Scatchard analysis clearly demonstrates the presence of a single class of high affinity somatostatin binding sites on MCF-7 cells. The specific binding of RC-160 and its lipophilized derivatives to somatostatin receptors on these cells were confirmed by displacement assays, using excess of cold peptides. Furthermore, RC-160 was found to interact with somatostatin receptors on human breast carcinoma cells via a pertussis toxin-sensitive GTP binding protein.
The somatostatin receptor subtype SSTR2 mediates the anti-proliferative effect of RC-160 in many cancer cell lines in vitro, by activation of a phosphotyrosine phosphatase. 4, 5, 30) The role of SSTR2 in the negative control of cell proliferation is further strengthened by the overexpression of this subtype in human breast cancer, small cell lung cancer (SCLC), pancreatic cancer, which respond in vitro and in vivo to the effect of somatostatin analogs. 4, 5) Hence, understanding the molecular interactions between RC-160 and SSTR2 is crucial, for designing analogs with better activity and stability profile than RC-160.
Molecular modeling has been done to elucidate the critical amino acid residues mediating the interaction of peptide analogs with SSTR2.
30) The putative binding pocket of SSTR2 is lined with hydrophobic residues, which are involved in lipophilic interactions with the aromatic residues of octreotide. Hence, the interactions of the somatostatin receptor subtype 2 with RC-160 appear to be primarily hydrophobic in character. The attachment of saturated fatty acids to RC-160 was done with the aim of increasing the peptide hydrophobicity (and consequently its receptor affinity), as well as to confer RC-160 with improved stability and increased resistance towards proteolytic degradation in serum.
However, the receptor affinity of pamitoyl RC-160 (as indicated by the IC 50 values) is only slightly higher, as compared to RC-160, in MCF-7 cells. Contrary to our belief, the receptor affinity does not seem to be significantly influenced by the increased hydrophobicity of RC-160. This also suggests that lipophilization does not seem to significantly affect the conformation of RC-160. This can be explained by the fact that there seems to be sufficient structural homology amongst G-protein-linked peptide receptors to accommodate up to large cyclic peptides at the binding site. 15) This is illustrated by the apparent utility of the somatostatin scaffold to develop highly selective and potent agonists and antagonists to a variety of other G-protein coupled neuropeptide receptors. 31, 32) However, there seems to be an optimum fatty acyl chain length beyond which lipophilized-RC-160 loses its affinity for somatostatin receptors on target cells. The receptor affinity of RC-160 is similar to its myristoylated or pamitoylated derivatives. A further increase in fatty acid chain length (stearoyl-RC-160) seems to diminish the receptor affinity of lipophilized RC-160. Stearoyl-RC-160 (carbon chain lengthϭ18) binds to somatostatin receptors on MCF-7 cells with the least affinity amongst the lipopeptides. This seems to correlate well with the observation that stearoyl-RC-160 also possessed the least anti-proliferative activity amongst the lipopeptides. An exception to this trend was butanoyl-RC-160 which displayed lower receptor affinity than the long chain lipopeptides. The coupling of butanoic acid to RC-160 may be causing a perturbation in the conformation of RC-160, which reduces its receptor affinity and anti-proliferative activity. However, the interesting fact is that despite the similar receptor affinities of RC-160 and pamitoyl RC-160, the latter displays a much greater anti-proliferative activity.
The dose-response profile of RC-160, to inhibit the growth of MCF-7 cells was found to be biphasic in nature, the maximal anti-proliferative activity being manifested in a narrow range of peptide concentration. All the three peptides inhibited tumor cell growth to the same magnitude, the cell number being decreased by approx. 40%. However, the long chain lipopeptides like pamitoyl RC-160 inhibit tumor cell growth at about a 10-fold lower concentration than RC-160, in the breast carcinoma cell line MCF-7. The anti-proliferative activity of RC-160 seems to increase with increasing carbon chain length of the lipopeptide. However, this improvement in anti-proliferative activity, seems to saturate around pamitoyl-RC-160 (carbon chain lengthϭ16). Most interestingly, there seems to be an optimum fatty acyl chain length beyond which lipophilized-RC-160 loses its antitumor activity on cancer cells. A further increase in carbon chain length of lipophilized-RC-160 causes a loss of the growth-inhibitory activities of lipophilized-RC-160. Stearoyl-RC-160 (carbon chain lengthϭ18) displayed significantly lower antineoplastic activity, as compared to its pamitoylated or myristoylated counterpart (pϽ0.001). An exception to the trend butanoyl RC-160, which was found to be a less potent derivative of RC-160 than the long chain lipopeptides. Similar to RC-160, the dose response of pamitoyl-RC-160, to inhibit cell growth was also found to be biphasic in nature. Previous studies have also found that the growth inhibitory effects of somatostatin agonists like octreotide and RC-160 are not concentration dependent; rather they display a biphasic pattern.
27) The precise mechanistic reason for this behavior is not known. According to Delesque et al., (1995) high doses of somatostatin can stimulate InsP 3 formation, which can abrogate its anti-proliferative activity, producing a biphasic pattern. 33) There is also accumulating evidence that high doses of somatostatin analogs can lead to receptor desensitization leading to loss of antitumor activity.
11) It is possible that the loss of antiproliferative activity may be occurring at least, in part, due to desensitization of somatostatin receptors on MCF-7 cells, by higher concentrations of somatostatin agonists.
The signaling pathways underlying the anti-proliferative activity of the lipopeptides seem to follow a similar pattern as RC-160. RC-160 and the lipopeptides were found to potently inhibit protein tyrosine kinase activity in MCF-7 cells. The long chain lipopeptide pamitoyl-RC-160 displays inhibition of tyrosine kinase activity at a 10-fold lower concentration, compared to RC-160. However the magnitude of inhibition of PTK activity is similar in all the three peptides (about 45-50% inhibition in PTK activity), in MCF-7 cells. Pawlikowski et al. (1998) and Keri et al. (1996) have demonstrated that somatostatin analogs mediate their anti-neoplastic effects by the inhibition of PTK activity, in several carcinomas. [34] [35] [36] The activation of protein tyrosine phosphatase, by SSTR2 has been recognized as one of the predominant signaling mechanisms mediating cell growth arrest (via SSTRs 1, 2, 4, or 5) or apoptosis (via SSTR3).
4) The somatostatin sensitive PTPase has been shown to inactivate and antagonize tyrosine kinase activity in several cancer cell lines. 4) Octapeptide analogs like octreotide have shown to activate PTPase and induce its translocation to the membrane, 26) in MCF-7 cells. Hence, it seems probable that the observed inhibition of tyrosine kinase activity in MCF-7 cells is being mediated through a SSTR2 dependent PTPase-sensitive pathway. 4) Furthermore, the anti-proliferative activity of RC-160 and the lipopeptides is sensitive to pertussis toxin, indicating that the anti-proliferative signal is transduced by pertussis toxin-sensitive GTP binding proteins.
The second messenger cAMP has been known to stimulate proliferation in certain mammalian cells and has been found to act as a mediator of mitogenic hormones.
2) RC-160 and the lipopeptides potently inhibited forskolin-stimulated intracellular cAMP levels in MCF-7 cells. Somatostatin analogs are coupled to adenylyl cyclase in intracellular signal transduction and have been found to inhibit the activation of adenylyl cyclase through a possible interaction through a Gprotein. 22) The activation of somatostatin receptors particularly SSTR2, produces a fall in intracellular cAMP levels, which in part mediates the anti-proliferative and anti-secretory activity of somatostatin. 4) All the peptides were found to inhibit forskolin-stimulated intracellular cAMP. However, pamitoyl-RC-160 displayed significantly enhanced inhibition of intracellular cAMP levels relative to butanoyl-RC-160 and RC-160 itself (pϽ0.01). The inhibition of intracellular cAMP levels, mediated by the lipopeptides was not dose-dependent. Furthermore, the maximal inhibition in cAMP and maximal antiproliferative activity, are displayed at the same concentrations of the RC-160 and the lipopeptides. These findings seem to suggest that the inhibition of intracellular cAMP may be important pathway mediating the anti-proliferative activity of lipophilized-RC-160. As mentioned previously, breast carcinoma cells are sensitive to mitogenic stimulation by a variety of growth factors and steroid hormones. 26, 27) The superior efficacy of lipophilized-RC-160 to inhibit both the anti-secretory and growth-inhibitory signaling pathways may be partially responsible for its improved anti-proliferative activity, relative to RC-160, in MCF-7 cells.
Studies are ongoing in the laboratory to gain further insight into signaling events underlying the anti-proliferative activity of these peptides.
The relative stability of these lipopeptides versus RC-160 was assessed by treating them with bovine pancreatic protease and serum. It was observed that pamitoyl-RC-160 was significantly more stable than RC-160 towards degradation by bovine pancreatic protease, as well as serum. This seems to suggest that the pamitoyl moiety of the lipopeptide shields the peptide against enzymatic and serum degradation. This may explain the improved anti-proliferative activity of pamitoyl-RC-160, as compared to RC-160. Pamitoyl-RC-160 does not get degraded quickly by proteases or serum, so is present in the cellular microenvironment for a greater length of time as compared to RC-160. The enhanced availability of pamitoyl-RC-160 in the cellular milieu possibly facilitates more efficient intracellular signaling, thereby causing it to display equivalent anti-proliferative activity at about a 10-fold lower concentration, as compared to RC-160, which is degraded quickly.
The above data seems to suggest that long chain lipopeptides like pamitoyl-RC-160 may be of potential importance in the therapy of breast carcinoma. However, the crucial issue remains whether lipophilized RC-160 will have greater antiproliferative activity, as compared to RC-160 in vivo. The antineoplastic activity of lipophilized RC-160 on tumor growth in vivo (in nude mouse model) is being investigated currently in our laboratory. However, the above data suggests that lipophilization of RC-160 lowers the optimum dose required for the inhibition of cancer cell growth without compromising its efficacy, thereby increasing the scope of improving its therapeutic index. However, this enhancement of biological activity occurs only within a certain narrow range of peptide hydrophobicity. Hence, optimizing the peptide hydrophobicity should be a key consideration in the rational design and synthesis of potent and selective lipopeptides.
